These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 22641380)

  • 21. Drug Delivery for Cancer Immunotherapy and Vaccines.
    Batty CJ; Tiet P; Bachelder EM; Ainslie KM
    Pharm Nanotechnol; 2018; 6(4):232-244. PubMed ID: 30227827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.
    Silva AL; Soema PC; Slütter B; Ossendorp F; Jiskoot W
    Hum Vaccin Immunother; 2016 Apr; 12(4):1056-69. PubMed ID: 26752261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.
    Mohsen MO; Heath MD; Cabral-Miranda G; Lipp C; Zeltins A; Sande M; Stein JV; Riether C; Roesti E; Zha L; Engeroff P; El-Turabi A; Kundig TM; Vogel M; Skinner MA; Speiser DE; Knuth A; Kramer MF; Bachmann MF
    J Immunother Cancer; 2019 Apr; 7(1):114. PubMed ID: 31027511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.
    Saxena M; Bhardwaj N
    Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The application of exosomes as a nanoscale cancer vaccine.
    Tan A; De La Peña H; Seifalian AM
    Int J Nanomedicine; 2010 Nov; 5():889-900. PubMed ID: 21116329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
    Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
    Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy.
    Huang P; Wang X; Liang X; Yang J; Zhang C; Kong D; Wang W
    Acta Biomater; 2019 Feb; 85():1-26. PubMed ID: 30579043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for pancreatic cancer: current concepts.
    Kaufman HL; Di Vito J; Hörig H
    Hematol Oncol Clin North Am; 2002 Feb; 16(1):159-97, viii. PubMed ID: 12063825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How can nanotechnology help membrane vesicle-based cancer immunotherapy development?
    Tian X; Zhu M; Nie G
    Hum Vaccin Immunother; 2013 Jan; 9(1):222-5. PubMed ID: 23108359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Part I: targeted particles for cancer immunotherapy.
    Hamdy S; Haddadi A; Ghotbi Z; Hung RW; Lavasanifar A
    Curr Drug Deliv; 2011 May; 8(3):261-73. PubMed ID: 21453265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyethylenimine Hybrid Thin-Shell Hollow Mesoporous Silica Nanoparticles as Vaccine Self-Adjuvants for Cancer Immunotherapy.
    Liu Q; Zhou Y; Li M; Zhao L; Ren J; Li D; Tan Z; Wang K; Li H; Hussain M; Zhang L; Shen G; Zhu J; Tao J
    ACS Appl Mater Interfaces; 2019 Dec; 11(51):47798-47809. PubMed ID: 31773941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nucleic Acid Nanoparticles at a Crossroads of Vaccines and Immunotherapies.
    Dobrovolskaia MA
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31861154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent progress in adjuvant discovery for peptide-based subunit vaccines.
    Azmi F; Ahmad Fuaad AA; Skwarczynski M; Toth I
    Hum Vaccin Immunother; 2014; 10(3):778-96. PubMed ID: 24300669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.
    Lynn GM; Laga R; Jewell CM
    Cancer Lett; 2019 Sep; 459():192-203. PubMed ID: 31185250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Particle platforms for cancer immunotherapy.
    Serda RE
    Int J Nanomedicine; 2013; 8():1683-96. PubMed ID: 23761969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer vaccines: an update.
    Hipp JD; Hipp JA; Lyday BW; Minev BR
    In Vivo; 2000; 14(5):571-85. PubMed ID: 11125541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.
    Grimaudo MA
    Adv Exp Med Biol; 2021; 1295():303-315. PubMed ID: 33543465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.